Skip to main content
. 2015 Feb 18;10(2):e0115270. doi: 10.1371/journal.pone.0115270

Table 2. Use of lipid-lowering therapy.

High-risk(SCORE ≥5%, or receiving LLT) Very-high-risk(SCORE ≥10%, or diabetes mellitus)
(n = 5019) (n = 2970)
Any LLT 3278 (65.3) 1469 (49.5)
Statins alone 2862 (87.3) 1299 (88.4)
Statins with additional non-statin LLT a 178 (5.4) 86 (5.9)
Non-statin LLT a 238 (7.3) 84 (5.7)

aNon-statin LLT: ezetimibe, fibrates, nicotinic acid, anion exchange resins.

LLT, lipid-lowering therapy; SCORE, Systematic Coronary Risk Evaluation.